



Ad hoc release

STADA: Preliminary figures show successful financial year 2013 – Dividend to increase by 32 percent – Outlook for 2014 confirmed

Bad Vilbel, March 3, 2014 – On the basis of the preliminary figures for financial year 2013, today March 3, 2014, the Executive Board of STADA Arzneimittel AG has taken a resolution on the dividend proposal for the past financial year. According to the proposal, the STADA Executive Board recommends that the Supervisory Board propose to the next Annual General Meeting on June 4, 2014 a dividend for financial year 2013 in the amount of Euro 0.66 per common share (previous year: Euro 0.50). This would represent an increase in dividend of 32 percent as compared to the previous year. The Executive Board also confirmed the forecast for financial year 2014 as given in 2010.

According to preliminary Group key figures, **Group sales** in 2013 are expected to have increased by 10 percent to Euro 2,014.4 million and thereby amount to over two billion euros for the first time. All reported and adjusted key earnings figures at the Group level are anticipated to show growth. **Reported EBITDA**, thereby, is expected to have increased by 18 percent to Euro 383.5 million. **EBITDA adjusted** for one-time special effects is estimated to have risen by 13 percent to Euro 415.2 million and thereby reached a new record high in corporate history. **Reported net income** recorded growth of an anticipated 40 percent to Euro 121.4 million. **Net income adjusted** for one-time special effects and effects from the measurement of derivative financial instruments within financial income and expenses is expected to have risen by 9 percent to Euro 160.6 million. **Reported earnings per share** are anticipated to have increased to Euro 2.04 (previous year: Euro 1.46). **Earnings per share adjusted** for one-time special effects and effects from the measurement of derivative financial instruments within financial income and expenses rose to an anticipated Euro 2.70 (previous year: Euro 2.50).

As of the balance sheet date, **net debt** is expected to come to Euro 1.306.8 million (December 31, 2012: Euro 1,177.3 million). As of December 31, 2013, the **net debt to adjusted EBITDA ratio** is expected to amount to 3.1 (previous year: 3.2).

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend



For the **outlook**, the Executive Board expects further growth and confirms the prognosis for financial year 2014 as given in 2010. According to this, Group sales of Euro 2.15 billion, adjusted EBITDA of Euro 430 million and adjusted net income of Euro 215 million could be reached.

STADA will publish its final figures for financial year 2013 on March 27, 2014.

STADA key figures at a glance

	2013 (approx. figures)	2012	+/-
Group sales	€ 2,014.4 million	€ 1,837.5 million	+10%
EBITDA	€ 383.5 million	€ 323.7 million	+18%
<i>EBITDA, adjusted</i>	<i>€ 415.2 million</i>	<i>€ 367.4 million</i>	<i>+13%</i>
Net income	€ 121.4 million	€ 86.5 million	+40%
<i>Net income, adjusted</i>	<i>€ 160.6 million</i>	<i>€ 147.9 million</i>	<i>+9%</i>
Earnings per share	€ 2.04	€ 1.46	+40%
<i>Earnings per share, adjusted</i>	<i>€ 2.70</i>	<i>€ 2.50</i>	<i>+8%</i>

Additional information:

STADA Arzneimittel AG / Corporate Communications / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / e-mail: communications@stada.de

Or visit us in the Internet at www.stada.com.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
 Chairman of the Supervisory Board: Dr. Martin Abend